Category: District of Delaware
-
Pfizer, BioNTech hit back against GSK mRNA suits in UPC, Ireland: file UK revocation actionÂ
The move does not come as a major surprise, given the pharma companiesâ previous success against GlaxoSmithKline in the UK.
-
Acer seeking counterleverage against Nokia through “threat letters” in U.S. despite highly asymmetric SEP portfolios and sales volumes: DJ action
Acer sent “threat letters” to U.S. telecommunications carriers using Nokia equipment, provoking a declaratory judgment complaint.
-
BREAKING: Nokia sues Paramount over video streaming patents in U.S. and Brazil, uses winning patents from Amazon ITC dispute
Nokia is serious about collecting video codec patent royalties from streamers. Its new enforcement action against Paramount is the latest example.
-
U.S. multijurisdiction panel consolidates four SAP trading software patent infringement disputes against Toronto Stock Exchange, Trayport in District of Delaware
The United States Judicial Panel on Multidistrict Litigation has ordered four SAP patent infringement cases filed against TSX Alpha, TSX Inc., and Trayport in three separate courts to be centralized in the District of Delaware.
-
Novo Nordisk suffers loss over negative claim limitation in ongoing patent dispute over diabetes drug Wegovy
The United States District Court for the District of Delaware has ruled that Viatris has not induced the infringement of one of five asserted patents in litigation initiated by Novo Nordisk.
-
U.S. appeals court grants Novartis short-term injunction in Entresto patent dispute with MSN: non-skilled-artisan testimony is key issue
The Federal Circuit has granted Novartis a few more days of Entresto exclusivity through a short-term injunction against MSN.
-
Walkie-Talkie maker Voxer sues Amazon, Twitch over video communication patents: previously prevailed over Meta
Voxer previously settled a major patent infringement dispute over similar video communication technologies with Meta in February 2024, after being awarded damages of over $206 million.
-
Novartis denied injunctive relief against MSN in chronic heart failure patent fight: next stop emergency motion for injunction pending appeal?
Novartis cannot block rival MSN Pharmaceuticals from launching a generic version of its chronic heart failure treatment Entresto before its patent expires in November 2026, the District of Delaware has held.